Deerfield Capital

BiomX Inc. is a clinical-stage company based in Ness Ziona, Israel, focused on developing bacteriophage-based therapies aimed at treating and preventing diseases linked to microbiome imbalances. The company’s innovative approach targets harmful bacteria associated with various conditions, including skin issues and chronic diseases such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. Its lead product candidates include BX001, aimed at improving skin appearance, and BX002, a therapeutic phage for inflammatory bowel disease. Additional candidates such as BX003 and BX004 target bacteria associated with liver disorders and chronic pulmonary infections, respectively. BiomX collaborates with esteemed institutions, including the Weizmann Institute of Science and MIT, to leverage cutting-edge research in microbiome modulation. Founded in 2015, BiomX is dedicated to advancing microbiome therapeutics through its robust development pipeline.

SpectraWAVE, Inc. is a medical device company based in Waltham, Massachusetts, founded in 2017. The company specializes in the development and manufacturing of optical diagnostic and therapeutic devices aimed at enhancing the diagnosis and treatment of cardiovascular diseases. Its flagship product includes a spectroscopy catheter that assists in diagnosing and treating cardiovascular conditions. SpectraWAVE has also developed an advanced intravascular imaging technology that integrates proven imaging methodologies to improve outcomes for coronary artery disease. This technology provides interventional cardiologists with critical optical and computational insights to optimize stent interventions and identify patients and plaques at risk of adverse coronary events, ultimately aiming to improve patient treatment and outcomes in the field of cardiovascular health.

Vesta Healthcare is a technology and clinical services organization based in New York, specializing in connecting caregivers to care teams through its innovative health care platform. The company offers 24/7 telehealth support aimed at caregivers and care recipients, particularly focusing on high-need, frail senior populations. Vesta partners with home care agencies, health plans, and healthcare providers to develop value-based population health programs that prioritize clinical quality and improved health outcomes. Founded in 2008 and originally known as Hometeam Technologies, Inc., Vesta Healthcare has established itself as a leader in enhancing caregiver insights and facilitating personalized engagement in the healthcare setting.

BiomX Inc. is a clinical-stage company based in Ness Ziona, Israel, focused on developing bacteriophage-based therapies aimed at treating and preventing diseases linked to microbiome imbalances. The company’s innovative approach targets harmful bacteria associated with various conditions, including skin issues and chronic diseases such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. Its lead product candidates include BX001, aimed at improving skin appearance, and BX002, a therapeutic phage for inflammatory bowel disease. Additional candidates such as BX003 and BX004 target bacteria associated with liver disorders and chronic pulmonary infections, respectively. BiomX collaborates with esteemed institutions, including the Weizmann Institute of Science and MIT, to leverage cutting-edge research in microbiome modulation. Founded in 2015, BiomX is dedicated to advancing microbiome therapeutics through its robust development pipeline.

Adela is a company focused on developing innovative technologies for the early detection of cancer and other serious health conditions through routine blood testing. Utilizing a genome-wide methylome enrichment platform, Adela captures and analyzes information from the entire methylome, effectively identifying and targeting highly informative methylated regions of the genome for sequencing. This approach enables the detection of minimal residual disease and aids in tumor classification using plasma cell-free DNA methylomes. Adela's technology is designed to assist healthcare professionals in cancer detection, as well as in prenatal diagnostics, cardiology, and the monitoring of immune responses. Through its advancements, Adela aims to improve diagnostic accuracy and patient outcomes in the realm of high-morbidity and high-mortality conditions.

Epic Sciences, Inc. is a diagnostics company based in San Diego, California, focused on improving cancer management through the development of highly sensitive tests that identify and characterize circulating tumor cells (CTCs) using minimally invasive blood samples. Founded in 2008, the company’s platform enables the profiling of single-cell phenotypes and genotypes, providing detailed information on biomarker expression levels, morphologic characteristics, and genetic changes. Epic Sciences offers the Oncotype DX AR-V7 Nucleus Detect test specifically for patients with metastatic castration-resistant prostate cancer, as well as biopharma solutions. The company collaborates with biotechnology and pharmaceutical firms, major cancer centers, and renowned research institutions, including the National Cancer Institute and the National Institutes of Health, to enhance personalized medicine and guide treatment decisions.

COTA, Inc. is a Boston-based company that specializes in developing a platform designed to provide data and insights related to cancer patients, aimed at guiding treatment decisions. Founded in 2011 by a team of doctors, engineers, and data scientists, COTA utilizes proprietary technology and advanced analytics to transform fragmented electronic health record (EHR) data into cohesive, research-grade information. This platform supports oncology practices and cancer centers by identifying variations in care, thus enabling the design of effective treatment programs and payment models. COTA's solutions serve a diverse range of stakeholders, including healthcare providers, payers, life sciences companies, and the FDA, ultimately striving to enhance patient outcomes and reduce healthcare costs associated with cancer care.

Epic Sciences, Inc. is a diagnostics company based in San Diego, California, focused on improving cancer management through the development of highly sensitive tests that identify and characterize circulating tumor cells (CTCs) using minimally invasive blood samples. Founded in 2008, the company’s platform enables the profiling of single-cell phenotypes and genotypes, providing detailed information on biomarker expression levels, morphologic characteristics, and genetic changes. Epic Sciences offers the Oncotype DX AR-V7 Nucleus Detect test specifically for patients with metastatic castration-resistant prostate cancer, as well as biopharma solutions. The company collaborates with biotechnology and pharmaceutical firms, major cancer centers, and renowned research institutions, including the National Cancer Institute and the National Institutes of Health, to enhance personalized medicine and guide treatment decisions.

Lark is a developer of a virtual platform focused on chronic disease prevention and management. Founded in 2011 by Julia Hu and Jeff Zira, the company is headquartered in Mountain View, California. Lark's platform leverages advanced artificial intelligence alongside human coaching and connected devices to offer real-time, personalized support and counseling. This approach aims to help users make healthier choices and effectively manage their chronic conditions. The company's programs, including those recognized by the CDC for diabetes prevention, wellness, diabetes care, and hypertension, serve approximately 1.5 million users. These initiatives have shown clinically validated improvements in health outcomes, as documented in multiple peer-reviewed journals and analyst reports.

HilleVax is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, founded in 2021. The company specializes in the development and commercialization of innovative vaccines. Its primary focus is on HIL-214, a virus-like particle (VLP) based vaccine candidate aimed at preventing moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. HilleVax is dedicated to addressing significant public health challenges through its vaccine initiatives.

GeneDx is a company dedicated to providing personalized and actionable health insights that enhance diagnosis and treatment, ultimately improving health outcomes. Positioned at the intersection of diagnostics and data science, GeneDx combines decades of genomic expertise with the capability to interpret clinical data at scale. The company focuses on accelerating the application of genomic information and large-scale clinical data to establish precision medicine as a standard practice in healthcare. GeneDx leads the transformation of healthcare through its comprehensive exome and genome testing services, leveraging one of the largest rare disease data sets in the world. The business operates through two segments: GeneDx, which generates the majority of its revenue, and Legacy Sema4 diagnostics.

Novocardia is dedicated to enhancing the delivery of cardiovascular care, aiming to support patients with heart and vascular diseases in achieving longer and healthier lives. The company operates a cardiovascular care delivery network that emphasizes improving the quality and value of care provided to patients. By fostering collaborative relationships with health plans and primary care partners, Novocardia facilitates the transition to value-based care. Its platform encompasses various capabilities, including the implementation of quality and process improvement initiatives and technology-enabled care delivery, thereby equipping cardiologists with the necessary tools to better serve their patients.

Adela is a company focused on developing innovative technologies for the early detection of cancer and other serious health conditions through routine blood testing. Utilizing a genome-wide methylome enrichment platform, Adela captures and analyzes information from the entire methylome, effectively identifying and targeting highly informative methylated regions of the genome for sequencing. This approach enables the detection of minimal residual disease and aids in tumor classification using plasma cell-free DNA methylomes. Adela's technology is designed to assist healthcare professionals in cancer detection, as well as in prenatal diagnostics, cardiology, and the monitoring of immune responses. Through its advancements, Adela aims to improve diagnostic accuracy and patient outcomes in the realm of high-morbidity and high-mortality conditions.

CareMax is a technology-enabled care platform focused on delivering value-based care and chronic disease management for seniors. The company operates a network of medical centers that provide a wide range of healthcare and social services. Additionally, CareMax has developed a proprietary software and services platform that offers data, analytics, and rules-based decision tools to assist physicians in their practice. This integrated approach aims to enhance the quality of care for seniors while managing their healthcare needs effectively across the United States.

Jaguar Gene Therapy is a clinical-stage biotechnology company focused on accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases. The company specializes in developing treatments that target nonworking or missing genes by introducing healthy copies back into the body to restore function. This approach aims to address significant unmet needs in healthcare by expediting the development of gene therapies from research to clinical application as safely and quickly as possible.

Vesta Healthcare is a technology and clinical services organization based in New York, specializing in connecting caregivers to care teams through its innovative health care platform. The company offers 24/7 telehealth support aimed at caregivers and care recipients, particularly focusing on high-need, frail senior populations. Vesta partners with home care agencies, health plans, and healthcare providers to develop value-based population health programs that prioritize clinical quality and improved health outcomes. Founded in 2008 and originally known as Hometeam Technologies, Inc., Vesta Healthcare has established itself as a leader in enhancing caregiver insights and facilitating personalized engagement in the healthcare setting.

Jaguar Gene Therapy is a clinical-stage biotechnology company focused on accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases. The company specializes in developing treatments that target nonworking or missing genes by introducing healthy copies back into the body to restore function. This approach aims to address significant unmet needs in healthcare by expediting the development of gene therapies from research to clinical application as safely and quickly as possible.

SpectraWAVE, Inc. is a medical device company based in Waltham, Massachusetts, founded in 2017. The company specializes in the development and manufacturing of optical diagnostic and therapeutic devices aimed at enhancing the diagnosis and treatment of cardiovascular diseases. Its flagship product includes a spectroscopy catheter that assists in diagnosing and treating cardiovascular conditions. SpectraWAVE has also developed an advanced intravascular imaging technology that integrates proven imaging methodologies to improve outcomes for coronary artery disease. This technology provides interventional cardiologists with critical optical and computational insights to optimize stent interventions and identify patients and plaques at risk of adverse coronary events, ultimately aiming to improve patient treatment and outcomes in the field of cardiovascular health.

Curation Health, LLC is a provider of a clinical decision support platform aimed at facilitating value-based care. Established in 2018 and headquartered in Annapolis, Maryland, the company offers a point-of-care platform that curates actionable risk adjustment insights prior to patient visits, captures accurate clinical opportunities during consultations, and verifies appropriate provider documentation post-visit. The platform is designed to integrate seamlessly with electronic health records, utilizing clinical and quality rules to enhance patient care and drive performance improvements in various healthcare programs, including Medicare Advantage plans and Medicaid risk programs. By enabling precise clinical documentation and supporting quality initiatives, Curation Health aims to optimize healthcare delivery and outcomes.

GeneDx is a company dedicated to providing personalized and actionable health insights that enhance diagnosis and treatment, ultimately improving health outcomes. Positioned at the intersection of diagnostics and data science, GeneDx combines decades of genomic expertise with the capability to interpret clinical data at scale. The company focuses on accelerating the application of genomic information and large-scale clinical data to establish precision medicine as a standard practice in healthcare. GeneDx leads the transformation of healthcare through its comprehensive exome and genome testing services, leveraging one of the largest rare disease data sets in the world. The business operates through two segments: GeneDx, which generates the majority of its revenue, and Legacy Sema4 diagnostics.

RubiconMD, Inc. is a healthcare technology company that offers an online platform facilitating communication between primary care clinicians and specialists through eConsults. Founded in 2013 and headquartered in New York, RubiconMD enables primary care providers to quickly seek guidance and opinions on medical cases, thereby enhancing patient care and reducing costs. The platform allows clinicians to identify specialists based on various criteria, such as ratings and experience, ensuring informed decision-making in patient management. Additionally, RubiconMD provides continuing medical education (CME) programs, including live and on-demand webinars, and features RubiconRx, a clinical pharmacy service that supports medication management for patients. The company serves a diverse clientele, including employers, community health centers, health plans, and direct primary care practices, and also offers services related to electronic health records, workflow integration, and clinician engagement.

Element Science, Inc. is a medical device and digital health company focused on developing innovative solutions for high-risk cardiovascular patients. Founded in 2011 and headquartered in San Francisco, California, the company specializes in a patch-based wearable cardioverter defibrillator (WCD) designed to monitor patients' heart activity and mitigate the risks associated with sudden cardiac death. Element Science integrates advanced machine learning algorithms with human-centered design principles and stringent electromechanical medical device standards to create a proprietary wearable digital platform. This platform aims to provide continuous protection for patients with heart disease, addressing critical health needs as they transition from hospital care to daily life.

Farapulse, Inc. is a medical technology company based in Menlo Park, California, that specializes in the development and commercialization of catheter-based tools aimed at treating atrial fibrillation. Founded in 2012 and formerly known as Iowa Approach, Inc., the company offers an innovative product called FARAWAVE, which features advanced tissue-selective pulsed field ablation (PFA) therapy. This therapy is designed for both endocardial and epicardial approaches to atrial fibrillation ablation. Farapulse's portfolio includes a variety of catheters, such as over-the-wire, deflectable, linear, and circumferential lesion catheters, enabling physicians to effectively isolate pulmonary veins and enhance the safety, accessibility, and cost-effectiveness of atrial fibrillation treatments for patients.

Vesta Healthcare is a technology and clinical services organization based in New York, specializing in connecting caregivers to care teams through its innovative health care platform. The company offers 24/7 telehealth support aimed at caregivers and care recipients, particularly focusing on high-need, frail senior populations. Vesta partners with home care agencies, health plans, and healthcare providers to develop value-based population health programs that prioritize clinical quality and improved health outcomes. Founded in 2008 and originally known as Hometeam Technologies, Inc., Vesta Healthcare has established itself as a leader in enhancing caregiver insights and facilitating personalized engagement in the healthcare setting.

Contessa, headquartered in Nashville, specializes in Home Recovery Care, a risk-based model that delivers inpatient-level care in patients' homes. Established in 2015, Contessa uses its proprietary health informatics platform to facilitate safe, affordable, and outcome-improving home care. The company offers turnkey solutions, providing upfront savings for health plans, enabling healthcare systems to reinvent their care delivery model by treating patients outside the hospital, and enhancing patient experience through better physician support.

Aerie Pharmaceuticals is a biotechnology company dedicated to the discovery, development, and commercialization of innovative therapies for various eye diseases. Founded in 2005, the company has its headquarters in Bridgewater, New Jersey, and research facilities in Research Triangle Park, North Carolina. Aerie's portfolio includes Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; Rocklatan, a fixed-dose combination of Rhopressa and latanoprost for similar indications; AVX-012, a clinical-stage product candidate for dry eye; and AR-1105 and AR-13503 sustained-release implants for retinal diseases. The company collaborates with DSM on research, development, and licensing agreements.

SHINE Technologies, LLC is a medical technology company that specializes in the production and supply of medical tracers and cancer treatment elements. It primarily manufactures and distributes molybdenum-99 (moly-99), a key isotope used in the diagnosis and staging of various diseases, including cancer and heart disease. Additionally, SHINE offers iodine-131 and iodine-125 for treating thyroid cancer and other abnormal thyroid conditions, as well as for diagnosing liver function, kidney blood flow, and urinary tract obstruction. The company also provides xenon-133 for evaluating lung function and blood flow, particularly in the brain. SHINE's products are used extensively in the United States and internationally. Founded in 2010, the company is headquartered in Janesville, Wisconsin, with an additional office in Alkmaar, the Netherlands.

Epic Sciences, Inc. is a diagnostics company based in San Diego, California, focused on improving cancer management through the development of highly sensitive tests that identify and characterize circulating tumor cells (CTCs) using minimally invasive blood samples. Founded in 2008, the company’s platform enables the profiling of single-cell phenotypes and genotypes, providing detailed information on biomarker expression levels, morphologic characteristics, and genetic changes. Epic Sciences offers the Oncotype DX AR-V7 Nucleus Detect test specifically for patients with metastatic castration-resistant prostate cancer, as well as biopharma solutions. The company collaborates with biotechnology and pharmaceutical firms, major cancer centers, and renowned research institutions, including the National Cancer Institute and the National Institutes of Health, to enhance personalized medicine and guide treatment decisions.

ReMed provides rehabilitation services, neurobehavioral services, and supported living for people with mild, moderate, and severe brain injuries. They offer residential, outpatient, and home and community-based treatment.

Concert Genetics, Inc. is a healthcare information technology company based in Franklin, Tennessee, that specializes in providing software and analytical tools to streamline the genetic testing process for a variety of stakeholders, including hospitals, clinicians, health plans, and laboratories. Established in 2010 and rebranded from NextGxDx Inc. in 2017, the company focuses on enhancing the selection, ordering, payment, and management of genetic tests. Its platform facilitates claim-to-test matching, supports utilization management, and offers insights for laboratories and health plans, thereby improving payment integrity and operational efficiency. Concert Genetics also provides an end-to-end genetic testing management solution, the Concert Genetics Benefit Program, which helps health plans ensure access to clinically appropriate genetic testing for their members. Through its comprehensive services, Concert Genetics aims to simplify the complexities of genetic testing, ultimately contributing to the advancement of precision medicine.

Adeptus Health is a healthcare organization focused on providing accessible emergency medical care through its network of freestanding emergency rooms and strategic partnerships with various healthcare providers. The organization operates First Choice Emergency Room in Texas, a network of independent freestanding emergency facilities equipped with advanced diagnostic radiology technology, including CT scans, ultrasounds, and digital X-rays, as well as on-site laboratories staffed by emergency-trained physicians and registered nurses. Additionally, Adeptus Health collaborates with University of Colorado Health to operate UCHealth Emergency Rooms in Colorado and partners with Dignity Health to manage Dignity Health Arizona General Hospital and other freestanding emergency rooms in Arizona. In Louisiana, the organization works with Ochsner Health System to enhance emergency care services. Through these initiatives, Adeptus Health aims to improve patient access to emergency medical services while minimizing wait times.

Adeptus Health is a healthcare organization focused on providing accessible emergency medical care through its network of freestanding emergency rooms and strategic partnerships with various healthcare providers. The organization operates First Choice Emergency Room in Texas, a network of independent freestanding emergency facilities equipped with advanced diagnostic radiology technology, including CT scans, ultrasounds, and digital X-rays, as well as on-site laboratories staffed by emergency-trained physicians and registered nurses. Additionally, Adeptus Health collaborates with University of Colorado Health to operate UCHealth Emergency Rooms in Colorado and partners with Dignity Health to manage Dignity Health Arizona General Hospital and other freestanding emergency rooms in Arizona. In Louisiana, the organization works with Ochsner Health System to enhance emergency care services. Through these initiatives, Adeptus Health aims to improve patient access to emergency medical services while minimizing wait times.

Farapulse, Inc. is a medical technology company based in Menlo Park, California, that specializes in the development and commercialization of catheter-based tools aimed at treating atrial fibrillation. Founded in 2012 and formerly known as Iowa Approach, Inc., the company offers an innovative product called FARAWAVE, which features advanced tissue-selective pulsed field ablation (PFA) therapy. This therapy is designed for both endocardial and epicardial approaches to atrial fibrillation ablation. Farapulse's portfolio includes a variety of catheters, such as over-the-wire, deflectable, linear, and circumferential lesion catheters, enabling physicians to effectively isolate pulmonary veins and enhance the safety, accessibility, and cost-effectiveness of atrial fibrillation treatments for patients.

Conventus Orthopaedics provides a range of orthopedic and sports medicine services. The physicians specialize in orthopedic surgery, reconstructive surgery, spine surgery, joint replacement, sports medicine, physical therapy, and operative care of fractures, arthritis, strains, sprains, and sports-related injuries. Conventus was formed by a team of medical professionals with the sole purpose of creating less invasive ways to treat challenging periarticular fractures. By leveraging advanced nitinol technology, the Conventus team has developed a platform technology that provides robust fixation and creates reliable repairs. The company was incorporated in 2009 and is based in Maple Grove, Minnesota.

Vital Access Corporation is a development stage company based in Salt Lake City, Utah, founded in 2006. The company specializes in the development of surgical and interventional technologies aimed at improving vascular access for patients and their caregivers. Its product offerings include vascular access ports, tissue management apparatus, and various systems designed to create and maintain vascular access. Through its innovative technologies, Vital Access seeks to enhance the treatment capabilities of physicians, ultimately aiming to improve patient care.

EndoChoice is a medical device company specializing in the development and commercialization of technologies for gastrointestinal (GI) care. Founded in 2008 and headquartered in Alpharetta, Georgia, the company offers a range of products that include single-use devices, diagnostics, infection control products, and endoscopic imaging systems tailored for GI specialists. One of its notable innovations is the Full Spectrum Endoscopy™ System, which features colonoscopes and gastroscopes equipped with multiple imagers, allowing for a wider field of view compared to traditional endoscopes. This technology has demonstrated its efficacy by detecting significantly more polyps during colonoscopy procedures. EndoChoice serves over 2,000 customers in the United States and collaborates with 34 distribution partners globally. The company was recognized by Inc. Magazine as one of the fastest-growing companies in the U.S. for four consecutive years prior to its acquisition by Boston Scientific in 2016.

Breathe Technologies, Inc. is a medical technology company based in Irvine, California, specializing in the development and manufacture of innovative respiratory therapies for patients with respiratory insufficiency diseases. Founded in 2005, the company focuses on creating non-invasive open ventilation systems designed to assist individuals suffering from conditions such as interstitial lung diseases and neuromuscular disorders. Breathe Technologies' products are employed across various medical settings, including intensive care units, general medical units, and pulmonary rehabilitation. The company emphasizes the design of lightweight, compact ventilator systems that enhance patient mobility while providing continuous ventilation. As a subsidiary of Hill-Rom, Inc., Breathe Technologies aims to empower healthcare providers and improve patient outcomes through reliable and accessible respiratory care solutions.

Conventus Orthopaedics provides a range of orthopedic and sports medicine services. The physicians specialize in orthopedic surgery, reconstructive surgery, spine surgery, joint replacement, sports medicine, physical therapy, and operative care of fractures, arthritis, strains, sprains, and sports-related injuries. Conventus was formed by a team of medical professionals with the sole purpose of creating less invasive ways to treat challenging periarticular fractures. By leveraging advanced nitinol technology, the Conventus team has developed a platform technology that provides robust fixation and creates reliable repairs. The company was incorporated in 2009 and is based in Maple Grove, Minnesota.

SHINE Technologies, LLC is a medical technology company that specializes in the production and supply of medical tracers and cancer treatment elements. It primarily manufactures and distributes molybdenum-99 (moly-99), a key isotope used in the diagnosis and staging of various diseases, including cancer and heart disease. Additionally, SHINE offers iodine-131 and iodine-125 for treating thyroid cancer and other abnormal thyroid conditions, as well as for diagnosing liver function, kidney blood flow, and urinary tract obstruction. The company also provides xenon-133 for evaluating lung function and blood flow, particularly in the brain. SHINE's products are used extensively in the United States and internationally. Founded in 2010, the company is headquartered in Janesville, Wisconsin, with an additional office in Alkmaar, the Netherlands.

SHINE Technologies, LLC is a medical technology company that specializes in the production and supply of medical tracers and cancer treatment elements. It primarily manufactures and distributes molybdenum-99 (moly-99), a key isotope used in the diagnosis and staging of various diseases, including cancer and heart disease. Additionally, SHINE offers iodine-131 and iodine-125 for treating thyroid cancer and other abnormal thyroid conditions, as well as for diagnosing liver function, kidney blood flow, and urinary tract obstruction. The company also provides xenon-133 for evaluating lung function and blood flow, particularly in the brain. SHINE's products are used extensively in the United States and internationally. Founded in 2010, the company is headquartered in Janesville, Wisconsin, with an additional office in Alkmaar, the Netherlands.

Aerie Pharmaceuticals is a biotechnology company dedicated to the discovery, development, and commercialization of innovative therapies for various eye diseases. Founded in 2005, the company has its headquarters in Bridgewater, New Jersey, and research facilities in Research Triangle Park, North Carolina. Aerie's portfolio includes Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; Rocklatan, a fixed-dose combination of Rhopressa and latanoprost for similar indications; AVX-012, a clinical-stage product candidate for dry eye; and AR-1105 and AR-13503 sustained-release implants for retinal diseases. The company collaborates with DSM on research, development, and licensing agreements.

Epion Health, Inc. is a developer of a patient engagement platform that offers a range of mobile health applications and content through a cloud-based solution. Founded in 2011 and headquartered in Roseland, New Jersey, the company enables patients to access health-related information on their smartphones or mobile devices, helping them learn about their health and prepare for medical visits. Additionally, the platform provides physicians with access to essential health information, including pre-loaded medical applications such as drug references, dosage calculators, and health assessments. By facilitating communication between patients and healthcare providers, Epion Health aims to enhance patient care and improve overall efficiency in the healthcare continuum.

Wellfount Corp., established in 2006 and headquartered in Indianapolis, Indiana, specializes in providing pharmacy services to nursing facilities. The company offers a range of services including utilization and compliance reviews, multi-dose and compliance packaging, daily deliveries, intravenous therapy, and customized invoicing. Wellfount also provides EHR application integration and medical record services, along with medications and consulting services. Through its innovative technologies, the company aims to improve patient care quality and reduce costs by streamlining medication management processes in long-term care facilities.

IMRIS is a company that designs, manufactures, and markets image-guided therapy systems aimed at enhancing the effectiveness of medical treatments. Its primary product, the VISIUS Surgical Theatre, integrates advanced imaging technologies such as magnetic resonance imaging, computed tomography, and fluoroscopy into multi-purpose surgical suites. This setup allows for intra-operative imaging, providing timely information to clinicians during surgical and interventional procedures. IMRIS primarily serves hospitals that offer clinical services in the neurosurgical, interventional neurovascular, spinal, and cardiovascular fields. The company operates globally, with a presence in North America, Europe, the Middle East, and the Asia-Pacific region, focusing on improving visualization and the overall therapy delivery process.

Pacific Biosciences specializes in human, microbial, plant, and animal genomics, focusing on areas such as infectious disease research. The company designs and manufactures sequencing systems that address complex genetic challenges, utilizing its innovative single molecule real-time (SMRT) sequencing technology to detect biological processes in real time. Its product offerings include the PacBio RS II and Sequel Systems, which facilitate the monitoring and analysis of biochemical reactions at the single-molecule level, along with consumables like SMRT cells and various reagent kits. Customers range from research institutions and commercial laboratories to pharmaceutical and agricultural companies, with sales conducted through direct channels in North America and Europe, and distribution partners in Asia, the Middle East, and Latin America. Founded in 2000 and headquartered in Menlo Park, California, Pacific Biosciences continues to advance genomics research and applications.

Cytokinetics is a late-stage biopharmaceutical company dedicated to discovering, developing, and commercializing innovative treatments that target muscle function. The company focuses on developing muscle activators and inhibitors for conditions characterized by reduced muscle performance, weakness, and fatigue, including diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. Utilizing small molecules specifically engineered to enhance muscle function and contractility, Cytokinetics aims to create investigational medicines that may improve the health span of individuals affected by serious cardiovascular and neuromuscular disorders.

Pacific Biosciences specializes in human, microbial, plant, and animal genomics, focusing on areas such as infectious disease research. The company designs and manufactures sequencing systems that address complex genetic challenges, utilizing its innovative single molecule real-time (SMRT) sequencing technology to detect biological processes in real time. Its product offerings include the PacBio RS II and Sequel Systems, which facilitate the monitoring and analysis of biochemical reactions at the single-molecule level, along with consumables like SMRT cells and various reagent kits. Customers range from research institutions and commercial laboratories to pharmaceutical and agricultural companies, with sales conducted through direct channels in North America and Europe, and distribution partners in Asia, the Middle East, and Latin America. Founded in 2000 and headquartered in Menlo Park, California, Pacific Biosciences continues to advance genomics research and applications.

Pacific Biosciences specializes in human, microbial, plant, and animal genomics, focusing on areas such as infectious disease research. The company designs and manufactures sequencing systems that address complex genetic challenges, utilizing its innovative single molecule real-time (SMRT) sequencing technology to detect biological processes in real time. Its product offerings include the PacBio RS II and Sequel Systems, which facilitate the monitoring and analysis of biochemical reactions at the single-molecule level, along with consumables like SMRT cells and various reagent kits. Customers range from research institutions and commercial laboratories to pharmaceutical and agricultural companies, with sales conducted through direct channels in North America and Europe, and distribution partners in Asia, the Middle East, and Latin America. Founded in 2000 and headquartered in Menlo Park, California, Pacific Biosciences continues to advance genomics research and applications.

Breathe Technologies, Inc. is a medical technology company based in Irvine, California, specializing in the development and manufacture of innovative respiratory therapies for patients with respiratory insufficiency diseases. Founded in 2005, the company focuses on creating non-invasive open ventilation systems designed to assist individuals suffering from conditions such as interstitial lung diseases and neuromuscular disorders. Breathe Technologies' products are employed across various medical settings, including intensive care units, general medical units, and pulmonary rehabilitation. The company emphasizes the design of lightweight, compact ventilator systems that enhance patient mobility while providing continuous ventilation. As a subsidiary of Hill-Rom, Inc., Breathe Technologies aims to empower healthcare providers and improve patient outcomes through reliable and accessible respiratory care solutions.